eFFECTOR Therapeutics, Inc. [NASDAQ: EFTR] in partnership with investigators at Baylor College of Medicine disclosed that it has discovered the positive results for Zotatifin in breast cancer. The study demonstrated that Zotatifin cure decelerated tumor growth in six out of eight syngeneic TNBC models without obvious toxicity.
The company has presented the new positive data for Zotatifin in animal models of triple-negative breast cancer (TNBC) at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The presentation labeled, “The RNA helicase EIF4A is a therapeutic vulnerability in triple-negative breast cancer.”
The study authors discovered that stopping eIF4A in p53-null models of mouse mammary tumorigenesis with Zotatifin has controlled the tumor via both tumor-intrinsic mechanisms as well as activation of host immune response. This activity is further reinforced with the addition of chemotherapy.
Furthermore, the Zotatifin cure also prevents proliferative and stem cell signaling pathways including E2F targets, G2/M checkpoints, as well as NOTCH signaling, and induces proteins involved in Interferon-α and Interferon-γ responses.
In addition, Zotatifin in conjunction with the mTOR inhibitor everolimus shown statistically substantial lengthy endurance compared to the use of these agents alone. eFFECTOR contemplates that Zotatifin may have therapeutic benefit in this difficult-to-treat subset of breast cancer patients, especially in conjunction with other FDA-authorized agents.